Top-News
Donnerstag,
30.05.2019 15:00
von
PR Newswire
| Aufrufe: 120
Cannabics Pharmaceuticals to Participate at the 9th Annual LD Micro Invitational in Bel Air, California
Eine Labormitarbeiterin bei einer mikroskopischen Untersuchung. (Symbolbild)
© Likoper / iStock / Getty Images Plus / Getty Images
http://www.gettyimages.de/
PR Newswire
TEL AVIV, Israel and BETHESDA, Maryland, May 30, 2019
TEL AVIV, Israel and BETHESDA, Maryland, May 30, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4 at 11:20AM PST at the Luxe Sunset Hotel in Bel Air, California.
Mr. Eyal Barad (CEO of Cannabics Pharmaceuticals) will be presenting and meeting with investors.
"This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, President at LD Micro. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community."
The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals. View Cannabics Pharmaceuticals' profile here: http://www.ldmicro.com/profile/CNBX.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.
LD started out as a newsletter highlighting unique companies and has transformed into several influential events annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1 (877) 424-2429
info@cannabics.com
http://www.cannabics.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-to-participate-at-the-9th-annual-ld-micro-invitational-in-bel-air-california-300859068.html
SOURCE Cannabics Pharmaceuticals Inc.
Werbung
Mehr Nachrichten zur Cannabics Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
